Product Description: Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models[1][2][3].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Cizeau J, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother. 2009 Jul-Aug;32(6):574-84. /[2]Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18(9):857-868. /[3]Bruce VJ, et al. Minimalist Antibodies and Mimetics: An Update and Recent Applications. Chembiochem. 2016 Oct 17;17(20):1892-1899.
CAS Number: 945228-49-9
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Apoptosis
Deutsch
English
